Bennicas & Associates’s GSK GSK Stock Holding History

Bennicas & Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-31,520	Closed	-$1.97M	–	86
2013 Q2	$1.97M	Buy	+31,520	New	+$2M	1.36%	30

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

Bennicas & Associates's GSK Position: Q3 2013 in Review

Bennicas & Associates sold out of GSK (GSK) in Q3 2013, closing a stake of 31,520 shares — an estimated $1.97M sold.

Bennicas & Associates first reported a position in GSK in Q2 2013 and held it in 1 quarter. The position peaked at $1.97M in Q2 2013. 635 funds tracked by Wall St. Rank hold GSK as of Q3 2013.

Bennicas & Associates reported no remaining GSK position as of Q3 2013 after selling out during the quarter.
Bennicas & Associates sold 31,520 GSK shares in Q3 2013, an estimated $1.97M.
Bennicas & Associates first reported a position in GSK in Q2 2013 and held it in 1 quarter.
Bennicas & Associates's GSK position peaked at $1.97M in Q2 2013.
635 funds tracked by Wall St. Rank held GSK as of Q3 2013.

Based on Bennicas & Associates's 13F filing for Q3 2013, filed 18 Oct 2013.